This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Abstract: Breast cancer is the leading cause of cancer related death in women between the ages of 40 and 55 and the second leading cause of cancer related death in women in the United States. Exposure to carcinogens in the environment, occupational setting, and diet are believed to be the reason for the discrepancy. Epidemiological studies demonstrate a positive association with breast cancer and cigarette smoke. Benzo(a)pyrene (B(a)P), a major component of cigarette smoke, has been shown to cause lung, liver, pancreatic, colon and breast cancer. B(a)P is biotransformed into reactive metabolites that produces DNA adducts and DNA strand breaks. Furthermore, B(a)P has been shown to transform human breast epithelial cells (MCF-10A)from a normal to a cancerous phenotype. Several OSCs Diallyl Sulfide (DAS), Diallyl Disulfide (DADS) and Diallyl Trisulfide (DATS) have been shown to prevent cancer by altering biotransformation. We hypothesize that these OSCs will prevent the transformation of normal human breast epithelial cells to a cancerous phenotype by altering the biotransformation of B(a)P thus preventing the production of B(a)P DNA adducts and the expression of genes involved in cell transformation. To test this hypothesis first we will treat MCF-10A cells with B(a)P and/or OSCs and determine if reactive metabolites are formed. Secondly, we will determine if B(a)P cause DNA strand breaks by comet assay analysis and DNA adducts via P32 Post labeling and if OSCs can prevent this DNA damage and enhance DNA repair over time. Next we will determine the ability of B(a)P to transform normal cell into a cancerous phenotype and the ability of OSCs to inhibit this transformation by treating the cells repeatedly with B(a)P and OSCs. The formation of colonies on soft agar will indicate the presence of transformed cells. Tumor development in nude mice implanted with these transformed cells will confirm neoplastic transformation. Finally, we will demonstrate that B(a)P and/or OSCs will alter the expression of genes associated with transformation and proliferation. Gene expression will be determined by Real Time PCR Array and confirmed by Western Blot Analysis. Results from this study will help elucidate the mechanism by which B(a)P causes breast cancer and how OSCs may prevent this cancer. Ultimately, better chemopreventive regimens and chemotherapeutic compounds would be developed for this research.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12RR003020-25
Application #
7959140
Study Section
Special Emphasis Panel (ZRR1-RI-3 (01))
Project Start
2009-06-01
Project End
2010-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
25
Fiscal Year
2009
Total Cost
$117,288
Indirect Cost
Name
Florida Agricultural and Mechanical University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
623751831
City
Tallahassee
State
FL
Country
United States
Zip Code
32307
Poku, Rosemary A; Salako, Olufisayo O; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells. Am J Cancer Res 7:1515-1527
Ntantie, Elizabeth; Fletcher, Jerrine; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer. Oncotarget 8:31726-31744
Mazzio, Elizabeth A; Soliman, Karam F A (2017) HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells. Cancer Genomics Proteomics 14:17-33
Godugu, Chandraiah; Doddapaneni, Ravi; Patel, Apurva R et al. (2016) Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res 33:137-54
Mochona, Bereket; Jackson, Timothy; McCauley, DeCoria et al. (2016) Synthesis and Cytotoxic Evaluation of Pyrrole Hetarylazoles Containing Benzimidazole/Pyrazolone/1,3,4-Oxadiazole Motifs. J Heterocycl Chem 53:1871-1877
Mazzio, Elizabeth A; Li, Nan; Bauer, David et al. (2016) Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med 16:467
Etukala, Jagan R; Zhu, Xue Y; Eyunni, Suresh V K et al. (2016) Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorg Med Chem 24:3671-9
Nkembo, Augustine T; Ntantie, Elizabeth; Salako, Olufisayo O et al. (2016) The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety. Oncotarget 7:68194-68205
Boakye, Cedar H A; Patel, Ketan; Doddapaneni, Ravi et al. (2016) Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. Colloids Surf B Biointerfaces 143:156-167
Odewumi, Caroline O; Latinwo, Lekan M; Ruden, Michael L et al. (2016) Modulation of cytokines and chemokines expression by NAC in cadmium chloride treated human lung cells. Environ Toxicol 31:1612-1619

Showing the most recent 10 out of 204 publications